...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World neurosurgery >Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience
【24h】

Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience

机译：新诊断胶质母细胞瘤患者中与Carmustine晶片和Bevacizumab合并化疗的优点和缺点：单一制度体验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

ObjectiveTo retrospectively determine the safety and efficacy of combined chemotherapy with carmustine (BCNU) wafer, bevacizumab, and temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma (GBM). MethodsA total of 54 consecutive newly diagnosed GBMs were resected at our institution between 2010 and 2016. Twenty-nine patients underwent BCNU wafer implantation into the resection cavity followed by standard radiochemotherapy with temozolomide (TMZ, Stupp regimen) plus additional bevacizumab treatment between 2013 and 2016. Twenty-five patients who underwent resection without BCNU implantation between 2010 and 2012 were enrolled as a control group; these patients were treated with the Stupp regimen and did not receive bevacizumab. This retrospective study included evaluation of progression-free survival and overall survival, plus comparisons between the combined therapy group and the control group. ResultsThere were no significant differences in age, sex, Karnofsky Performance Status on admission, isocitrate dehydrogenase 1/2 mutation ratio, or resection rate between the combined and standard therapy groups. The median overall survival in the combined therapy group and control group was 24.2 months and 15.30, respectively (P?=?0.027). The median progression-free survival was 16.8 months and 7.30 months, respectively (P?= 0.009).Overall, the incidence of adverse events leading to discontinuation of the study drug was similar between the treatment groups, except for infection, which was more common in the combined treatment group and required repeat surgery. ConclusionsThe combined therapy showed higher efficacy compared with standard therapy in patients with GBM. Therefore, combined therapy seems to be effective with an acceptable toxicity profile.
机译：ObjectiveTo回顾性地确定组合化疗与甘蔗蛋白酶（BCNU）晶圆，贝伐单抗和替替莫唑胺加放射治疗新诊断的胶质母细胞瘤（GBM）的疗效。 MethaSa在2010年至2016年之间，在我们的机构中​​分发了54例连续的新诊断的GBMS .20九九患者接受了BCNU晶圆植入切除腔的植入术，然后用替替替莫唑胺（TMZ，STUPP方案）加上2013年和2016年之间的额外贝伐单抗治疗。2010年至2012年间未经BCNU植入未经BCNU植入的二十五名患者入学，作为对照组;这些患者被愚蠢的方案治疗，没有接受贝伐单抗。该回顾性研究包括评估无进展的存活和整体存活，以及联合治疗组和对照组之间的比较。结果没有显着差异，性别，karnofsky患者入院时，异柠檬酸脱氢酶1/2突变比，或联合治疗组之间的切除率。联合治疗组和对照组的中位数存活分别为24.2个月和15.30点（P？= 0.027）。中位进展生存率分别为16.8个月和7.30个月（P？= 0.009）.overall，导致研究药物中停止的不良事件发生率在治疗组之间相似，除感染外，更为常见在组合治疗组和所需的重复手术中。结论与GBM患者的标准治疗相比，组合治疗表现出更高的疗效。因此，组合治疗似乎是有效的，可接受的毒性概况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号